Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 19, 2019 / 02:45PM GMT
Release Date Price: $58.09 (+0.54%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks. So my name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be sitting here with Wade Walke, who's the Vice President of Investor Relations at Ionis. I think we're just going to have Wade kick it off with a 3-minute intro on the company and maybe review recent pipeline and commercial updates on the quarter, and then we can get into Q&A. So Wade, please take it away.

D. Wade Walke
Ionis Pharmaceuticals, Inc. - VP of IR

Thanks, Paul. Thanks for inviting me to the conference. Happy to be here. I'm sure a lot of you know about Ionis Pharmaceuticals. We're the leader in RNA-targeted antisense therapy. We have a large pipeline of more than 40 drugs in development. A lot of those in mid- to late-stage development. This year, we'll have 4 programs in Phase III and I think we have over 10-or-so in Phase II development. So a pretty large pipeline of mid- to late-stage assets.

We've developed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot